A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Canadian Cancer Trials Group
University of California, San Francisco
Masonic Cancer Center, University of Minnesota
H. Lee Moffitt Cancer Center and Research Institute
University of Miami
National Cancer Center, Korea
National Cancer Center, Korea